Two Dose Levels of Privigen in Pediatric CIDP
Recruiting · Phase 4 · NCT03684018
Conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
At a glance
- Research payments reported, 2025
- $59,913
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- CSL Behring
- Tested
- IgPro10 (biological)
- Dates
- Started 2019-02-28; completion 2029-12-20
- Results posted
- Not yet
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
From ClinicalTrials.gov, last updated 2026-06-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Csl Behring reported $59,913 in research payments for this study in 2025 (25 payments).
Products named: Privigen
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Saunder M. Bernes, M.D. Child Neurology · Phoenix, AZ
- Maria Escolar Pediatrics · Chapel Hill, NC
- John F. Brandsema, MD Child Neurology · Philadelphia, PA
- Diana P. Castro, MD Child Neurology · Denton, TX
- Crystal M. Proud, M.D. Child Neurology · Norfolk, VA
- Seth J. Perlman, MD Child Neurology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Neurology Rare Disease Center PLLC $30,228
- Seattle Children's Hospital, WA $12,091
- Children's Hosp of Los Angeles, CA $6,225
- Children's Hospital of Philadelphia, PA $4,960
- Phoenix Children's Hospital, AZ $4,159
- Children's Specialty Group, PLLC $2,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.